AstraZeneca: first European approval in blood cancers
(CercleFinance.com) - AstraZeneca's Calquence has been approved in the European Union for the treatment of adult patients with chronic lymphocytic leukaemia, the most common type of blood cancer, the drugmaker said on Monday.
The approval by the European Commission was based on positive results from two Phase III clinical trials, which showed a significant improvement relative to current standard treatments, the company said.
"One of our biggest hurdles in treating chronic lymphocytic leukaemia is finding tolerable treatment options that manage the disease long term, which typically impacts older patients with comorbidities", noted Paolo Ghia, a researcher at Milan's Universite Vita-Salute San Raffaele who investigated the trial.
"Today's news marks great progress for patients," he added.
This is AstraZeneca's first European approval in blood cancers.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The approval by the European Commission was based on positive results from two Phase III clinical trials, which showed a significant improvement relative to current standard treatments, the company said.
"One of our biggest hurdles in treating chronic lymphocytic leukaemia is finding tolerable treatment options that manage the disease long term, which typically impacts older patients with comorbidities", noted Paolo Ghia, a researcher at Milan's Universite Vita-Salute San Raffaele who investigated the trial.
"Today's news marks great progress for patients," he added.
This is AstraZeneca's first European approval in blood cancers.
Copyright (c) 2020 CercleFinance.com. All rights reserved.